1102308001_UNITED NATIONS_MH002017_BS.pdf
MAJOR COST SHARING PROVISIONS PARTICIPATING PROVIDER
Benefit Period
Maximum Out-of-Pocket Limit
Plan Year
Covered in full
$6,600 Individual / $13,200 Family
PCP Office visits
Specialist Office visits Covered in full Hospital admission No Copayment
Emergency Room copay (waived if Hospital admission) Covered in full
Prescription Drug Deductible Not Applicable
Prescription drugs – 30 day supply $5 generic / $5 brand
Prescription drugs – 90 day supply $7.50 generic / $7.50 brand
INPATIENT HOSPITAL SERVICES PARTICIPATING PROVIDER
• Hospital and physician services
• Semi-private room and board
Subject to Hospital Admission Copayment Physician Services Covered in Full
Included in Hospital Admission Copayment
• Operating and recovery room, intensive and special care units, general nursing care, prescribed drugs,anesthesia, X-rays, lab tests, mastectomy care, cardiac and pulmonary rehabilitation and end of life care
Included in Hospital Admission Copayment
• Inpatient Rehabilitation & Habilitation Services (Physical,Speech and Occupational Therapy)
Subject to Hospital Admission Copayment; 90 days combined therapies
• Human organ transplants Included in Hospital Admission Copayment
MATERNITY AND NEW BORN CARE PARTICIPATING PROVIDER
• Prenatal care Covered in full
• Inpatient Hospital Services and Birthing Center Covered in full
• Physician and Midwife Services for Delivery Covered In Full
• Breast Pump Covered in full
• Postnatal care Covered in full
Medical Deductible Not Applicable
SUMMARY OF BENEFITS
HIP Prime Network
UNITED NATIONS
PrimeHMO for NY CT and NJ Residents
1102308
(continued on next page) MH002017
SUMMARY OF BENEFITS
HIP Prime Network
UNITED NATIONS
PrimeHMO for NY CT and NJ Residents
1102308 • Postnatal care Covered in full SURGICAL SERVICES PARTICIPATING PROVIDER
• Inpatient Hospital Surgery Covered in full
• Outpatient Hospital Surgery Covered in full
• Surgery performed in a PCP Office Covered in full
• Surgery performed in a Specialist Office Covered in full
• Surgery performed at an Ambulatory Surgical Center Covered in full
CARDIAC REHABILITATION PARTICIPATING PROVIDER
• Performed as Inpatient Hospital Services Included as part of Inpatient Hospital Service Cost-Sharing
• Performed as Outpatient Hospital Services Covered in full ; 32 visits, combined with Specialist Officelimits
• Performed in a Specialist Office Covered in full ; 32 visits, combined with OutpatientHospital limits
OUTPATIENT MEDICAL CARE PARTICIPATING PROVIDER • PCP office visits Covered in full
• Specialists office visits Covered in full
• Preventive care, including well-child visits and immunizations, adult annual physical examinations, adult immunizations, routine gynecological services/well woman exams, mammograms, screening and diagnostic imaging for the detection of breast cancer, sterilization procedures for women, and bone density testing
Covered in full
• Laboratory Procedures, • Performed in a PCP Office
• Performed in Specialist Office
• Performed in a Free Standing Laboratory • Performed as Outpatient Hospital Services
Covered in full
Covered in full Covered in full
Covered in full
• Diagnostic Radiology
• Performed in a PCP Office
• Performed in Specialist Office
• Performed in a Free Standing Radiology Facility
• Performed as Outpatient Hospital Services
Covered in full
Covered in full
Covered in full
Covered in full
• Diagnostic Testing
• Performed in a PCP Office Covered in full
(continued on next page) MH002017
SUMMARY OF BENEFITS
HIP Prime Network
UNITED NATIONS
PrimeHMO for NY CT and NJ Residents
1102308 • Performed in a PCP Office
• Performed in Specialist Office
• Performed as Outpatient Hospital Services
Covered in full
Covered in full
Covered in full
• Advanced Imaging Services (PET scans, MRI, nuclear medicine, CAT scans)
• Performed in a Specialist Office
• Performed in a Free Standing Radiology Facility
• Performed as Outpatient Hospital Services
Covered in full
Covered in full
Covered in full
• Infusion Therapy
• Performed in a PCP Office
• Performed in a Specialist Office Referral required
• Performed as Outpatient Hospital Services
• Home Infusion Therapy
Covered in full
Covered in full
Covered in full
Covered in full
• Ambulatory surgery center facility Covered in full
• Outpatient hospital surgery facility Covered in full
• Preadmission testing Covered in full
• Second opinions on the diagnosis of cancer, surgery and other
90 visits, combined therapies • Outpatient Habilitation Services
Covered in full
• Performed in a PCP Office
• Performed in a Specialist Office
• Performed as Outpatient Hospital Services
Covered in full
Covered in full
Covered in full
• Radiation therapy
• Performed in a Specialist Office
• Performed in a Free Standing Radiology Facility
Covered in full
Covered in full
• Performed as Outpatient Hospital Services Covered in full
OUTPATIENT MEDICAL CARE PARTICIPATING PROVIDER
(continued on next page) MH002017
SUMMARY OF BENEFITS
HIP Prime Network
UNITED NATIONS
PrimeHMO for NY CT and NJ Residents
1102308 • Performed as Outpatient Hospital Services Covered in full
• Chemotherapy
• Performed in a PCP Office
• Performed in a Specialist Office
Covered in full
Covered in full
• Performed as Outpatient Hospital Services Covered in full
• Outpatient Rehabilitation Services(physical therapy,occupational therapy, speech therapy, pulmonary rehabilitation)
• Performed in a PCP Office
• Performed in a Specialist Office
Covered in full
Covered in full
• Performed as Outpatient Hospital Services Covered in full
• Allergy Testing and Treatment
• Performed in a PCP Office Covered in full
• Performed in a Specialist Office Covered in full
• Acupuncture Not Covered
• Telemedicine Program Provided by a Telemedicine Physician Not Covered
MENTAL HEALTH AND ALCOHOL AND SUBSTANCE USE SERVICES PARTICIPATING PROVIDER • Mental Health Care
• Inpatient Covered in full, Unlimited Days
• Outpatient Covered in full, Unlimited Visits
• Substance Use Services
• Inpatient Covered in full, Unlimited Days
• Outpatient Covered in full
SPECIAL KINDS OF CARE PARTICIPATING PROVIDER Urgent Care Center Covered in full
Non-Emergency Ambulance Services Covered in full Pre-Hospital Emergency Medical Services (Ambulance Services) Covered in full
90 visits, combined therapies
OUTPATIENT MEDICAL CARE PARTICIPATING PROVIDER
(continued on next page) MH002017
SUMMARY OF BENEFITS
HIP Prime Network
UNITED NATIONS
PrimeHMO for NY CT and NJ Residents
1102308 Pre-Hospital Emergency Medical Services (AmbulanceServices) Covered in full
Home health care Covered in full; 200 visits
Hospice care
Skilled Nursing Facility (including cardiac and pulmonary rehabilitation) Covered in full, Unlimited Days
Dialysis treatment
• Performed in PCP Office
• Performed in Specialist Office
$10 Copayment
$10 Copayment
• Performed in Free Standing Center $10 Copayment
• Performed as Outpatient Hospital Services $10 Copayment
Diabetes equipment, supplies, Insulin and education Covered in full
Chiropractic Services Covered in full
Family Planning Services Covered Vasectomy Covered in full
Infertility Diagnosis and Treatment 3 Cycles IVF, Per Lifetime, Subject To ApplicableCopayment Dental Care • Preventive Dental Preventive Included
Durable Medical Equipment and Braces No Deductible, Covered In Full
Prosthetics Covered In Full
Orthotics Covered In Full
Medical Supplies Covered in full
External Hearing Aids Not Covered
Cochlear Implants No Copayment - One (1) per ear per time Covered
Optical Care
• Refractive Eye Exams Covered in full / Once per covered period
• Eyeglasses Eyeglasses $35 Every 24 Months
ABA Treatment for Autism Spectrum Disorder Covered in full Assistive Communication Devices for Autism Spectrum Disorder Covered in full
Covered in full, 210 days
SPECIAL KINDS OF CARE PARTICIPATING PROVIDER
(continued on next page) MH002017
SUMMARY OF BENEFITS
HIP Prime Network
UNITED NATIONS
PrimeHMO for NY CT and NJ Residents
1102308 Assistive Communication Devices for Autism SpectrumDisorder Covered in full ADDITIONAL BENEFITS PARTICIPATING PROVIDER
• Nurse Advice Line Not Covered
• WellSpark Not Covered
• Gym Reimbursement Not Covered
FOOTNOTES
Drugs are dispensed in accordance with EmblemHealth’s Drug Formulary.
Language:English
Score: 553903.9
-
https://www.un.org/insurance/s.../files/hip_medical_plans_0.pdf
Data Source: un
This paper presents a case for a regional push towards the development and implementation of key
performance indicators within the performance areas being addressed by the ongoing APIRG
projects, in order to:
Enable the participation of the AFI region in Sharing performance issues/bench marking of best practices at the regional and global level,
Develop business cases for ASBU Module implementation with investment based on KPIs;
Inform future decisions on timeliness and appropriateness of ASBU Module deployment according to a performance-driven approach;
Measure and document the performance benefits brought by the ASBU Modules implemented under APIRG Projects
Action: The meeting is invited to agree to the recommendations in paragraph 3.
(...) The Global Air Navigation Plan recommends a phased
development approach for adoption of key Performance indicators by States, noting that States are
at different levels in regard to Performance measurement as the basis for the air navigation system
improvements.
2. DISCUSSION
2.1 Motivated by the need for a Data Driven Performance Management of Air
Navigation Services in Kenya, an ANS operational Performance measurement and monitoring
(OPMM) framework was developed as part of the Kenya Airspace Master plan 2015-2030.
Language:English
Score: 553437.3
-
https://www.icao.int/ESAF/Docu...ed%20to%20ASBU%20framework.pdf
Data Source: un
On 30 October 2019, the Expert Group held a brainstorming session on the fourth cycle of environmental performance reviews, including the main objectives and scope of the fourth cycle, the possible content and structure of the reviews, procedural aspects of conducting environmental performance reviews and ways to enhance the implementation of environmental performance review recommendations. (...) Environmental performance reviews will continue to be carried out at the country level.
(...) The Environmental Performance Review Unit should seek advice from the Expert Group on Environmental Performance Review on the need and modalities for deeper coverage of human rights and environment in environmental performance reviews.
19.
Language:English
Score: 553191.65
-
https://unece.org/sites/defaul...icosia.conf_.2022.12.e_aec.pdf
Data Source: un
On 30 October 2019, the Expert Group held a brainstorming session on the fourth cycle of environmental performance reviews, including the main objectives and scope of the fourth cycle, the possible content and structure of the reviews, procedural aspects of conducting environmental performance reviews and ways to enhance the implementation of environmental performance review recommendations. (...) Environmental performance reviews will continue to be carried out at the country level.
(...) The Environmental Performance Review Unit should seek advice from the Expert Group on Environmental Performance Review on the need and modalities for deeper coverage of human rights and environment in environmental performance reviews.
19.
Language:English
Score: 553191.65
-
https://unece.org/sites/defaul...ECE_NICOSIA.CONF_2022_12_E.pdf
Data Source: un
Lessons Learned and Best Practices from past Performance Review
Considering this is the first SPRFMO Performance Review, it has been a learning process for the Organisation. (...) Actions needed to further strengthen the effectiveness of the Performance Review Process
The SPRFMO Commission has not elaborated yet on further strengthening the Performance Review process. (...) Implementation of the Recommendation of Performance Review
4. Lessons Learned and Best Practices from past Performance Review
1.
5.
Language:English
Score: 552880.03
-
https://www.un.org/depts/los/c...s/ICSP14/RFBs&RFMOs/SPRFMO.pdf
Data Source: un
The Performance Review panel consisted of three external experts and three internal experts. (...) The Report and recommendations of NAFO’s 2018 Performance Review can be found at this link:
https://www.nafo.int/Portals/0/PDFs/Performance/NAFOPerformanceReviewPanelRpt2018.pdf
The Report and recommendations of NAFO’s first Performance Assessment Review in 2011 can be found at this link:
https://www.nafo.int/Portals/0/PDFs/Performance/PAR-2011.pdf
(i) the scope of performance reviews of regional fisheries management organizations and arrangements and the importance and role of such reviews for the implementation of the Agreement;
The scope of the 2018 NAFO Performance Review was determined by NAFO Contracting Parties (CPs), which formed a Working Group to develop the Performance Review’s Terms of Reference.
(...) To evaluate how NAFO has responded to the outcome of 2011 NAFO Performance Review (PR 1), taking into consideration the work and practices of NAFO's bodies, subsidiary bodies and working groups to date, and also the implementation of the action plan resulting from the recommendations of the 2011 NAFO Performance Review.
https://www.nafo.int/Portals/0/PDFs/Performance/NAFOPerformanceReviewPanelRpt2018.pdf
https://www.nafo.int/Portals/0/PDFs/Performance/NAFOPerformanceReviewPanelRpt2018.pdf
https://www.nafo.int/Portals/0/PDFs/Performance/PAR-2011.pdf
https://www.nafo.int/Portals/0/PDFs/Performance/PAR-2011.pdf
https://www.nafo.int/Portals/0/PDFs/com/2017/comdoc17-21.pdf
https://www.nafo.int/Portals/0/PDFs/com/2017/comdoc17-21.pdf
3
2.
Language:English
Score: 552815.4
-
https://www.un.org/depts/los/c...nts/ICSP14/RFBs&RFMOs/NAFO.pdf
Data Source: un
Scope of performance reviews of RFMO/As and importance of such reviews for the implementation of the treaty
Our experience has shown there is a wide degree of variation in the scope, rigour and depth of RFMO/A performance reviews. (...) Process and structure of performance review of RFMO/As, including related to independent evaluation, participation, transparency, accountability and periodicity
ISSF has participated in both committee-based performance reviews and independent performance reviews. (...) Accountability: remains one of the most important aspects of the performance review process. In subsequent performance reviews it is critical that review panels are tasked to assessing the actions taken in relation to the recommendations of the previous performance review.
Language:English
Score: 552791.1
-
https://www.un.org/depts/los/c...greements/ICSP14/NGOs/ISSF.pdf
Data Source: un
Mapping of IMDRF essential principles to AI for health software - Att.1 - Spreadsheets for cluster creation
Cover
FGAI4H-G-038-A01
New Delhi, 13-15 November 2019
Source:
WG DAISAM chairs
Title:
Mapping of IMDRF essential principles to AI for health software - Attachment 1 - Spreadsheets for cluster creation
Abstract:
This spreadsheet contains four worksheets that document how clusters were created for the main contribution.
key concepts
Chronology
Keyword
Section
5
Acceptable risks
5.1.1
109
Accuracy
5.8.1
197
Accuracy
5.12.2
245
Accuracy of measurements (trueness and precision)
7.2.1
40
Alarms
5.1.3
44
Alarms
5.1.3
235
Analytical performance
7.2.1
247
Analytical sensitivity/Limit of detection
7.2.1
249
Analytical specificity
7.2.1
301
Appropriate representation
7.2.4
77
Benefit-risk determination
5.2.1
275
Calibrators
7.2.2
136
Change management process
5.8.2
75
Clinical evaluation
5.2.1
83
Clinical experience
5.2.1
79
Clinical investigation report
5.2.1
237
Clinical performance
7.2.1
255
Clinical performance
7.2.1
145
Connectivity
5.8.3
57
Consider user knowledge
5.1.5
15
Continuous, iterative risk management
5.1.2
27
Continuous, iterative risk management
5.1.2
28
Continuous, iterative risk management
5.1.2
143
Contrast ratio of the screen
5.8.3
277
Control materials
7.2.2
271
Control procedures
7.2.1
161
Cybersecurity
5.8.5
88
Declaration of Helsinki
5.2.2
257
Diagnostic/clinical sensitivity
7.2.1
259
Diagnostic/clinical specificity
7.2.1
171
Easily understood
5.10.1
186
Easy to apply
5.12.1
184
Easy to understand
5.12.1
86
Ehtical prinicples
5.2.2
103
Electronic programmable systems
5.8.1
303
Ethnicity
7.2.4
63
Expected life of device
5.1.6
267
Expected values in normal and affected populations.
7.2.1
149
External factors related to their use (varying environment as regards level of light or noise)
5.8.3
228
Failure
5.12.3
24
Foreseeable misuse
5.1.2
305
Gender
7.2.4
307
Genetic diversity
7.2.4
210
Handling
5.12.2
153
Hardware
5.8.4
7
Health
5.1.1
21
Identify and analyze hazards
5.1.2
165
Information [Manual]
5.10.1
130
Information security (e.g., safely implement updates)
5.8.2
98
Informed consent
5.2.2
182
Instructions
5.12.1
199
Instructions
5.12.2
54
Intended usage environment
5.1.5
23
Intended use
5.1.2
62
Intended use
5.1.6
178
Intended use
5.12.1
222
Intended use
5.12.3
273
Intended use
7.2.1
293
Intended use
7.2.4
297
Intended use environment
7.2.4
295
Intended user
7.2.4
2
Intendeded conditions of use
5.1.1
212
Interpretation of results
5.12.2
155
IT networks characteristics
5.8.4
157
IT security measures
5.8.4
174
Lay user
5.12.1
188
Lay user
5.12.2
214
Lay users
5.12.3
100
Leftover specimen
5.2.2
265
Likelihood ratios
7.2.1
17
MD life cycle
5.1.2
251
Measuring interval/range
7.2.1
147
Memory
5.8.3
151
Minimum requirements
5.8.4
139
Mobile computing platforms
5.8.3
192
Near-patient testing
5.12.2
218
Near-patient testing
5.12.3
263
Negative predictive value
7.2.1
285
Numerical values
7.2.3
6
Patient benefits
5.1.1
4
Perform as intended
5.1.1
1
Performance
5.1.1
14
Performance
5.1.2
117
Performance
5.8.1
169
Performance
5.10.1
224
Performance
5.12.3
233
Performance characteristics
7.2.1
291
Performance evaluation
7.2.4
261
Positive predictive value
7.2.1
96
Pre-study protocol review
5.2.2
113
Precision
5.8.1
311
Prevalence rates
7.2.4
126
Principles of development life cycle (e.g., rapid development cycles, frequent changes, the cumulative effect of changes)
5.8.2
159
Protection against unauthorized access
5.8.4
163
Protection against unauthorized access
5.8.5
81
Published scientific literature
5.2.1
11
Quality
5.1.2
283
Reference materials of higher order
7.2.2
281
Reference measurement procedures
7.2.2
299
Relevant population
7.2.4
111
Reliability
5.8.1
309
Representative population
7.2.4
48
Residual risk information for user
5.1.4
90
Rights
5.2.2
22
Risk
5.1.2
70
Risk
5.1.9
26
Risk control
5.1.2
38
Risk control
5.1.3
32
Risk control measures
5.1.3
25
Risk elimination
5.1.2
128
Risk management (e.g., changes to system, environment, and data)
5.8.2
20
Risk management plan
5.1.2
9
Risk management system
5.1.2
208
Risk of error
5.12.2
50
Risk reduction
5.1.5
52
Risk reduction
5.1.5
121
Risk reduction
5.8.1
201
Risk reduction
5.12.2
206
Risk reduction
5.12.2
42
Risks that cannot be eliminated
5.1.3
39
Safe design
5.1.3
3
Safety
5.1.1
12
Safety
5.1.2
92
Safety
5.2.2
115
Safety
5.8.1
167
Safety
5.10.1
195
Safety
5.12.2
34
Safety principles compliance
5.1.3
176
Self-testing
5.12.1
190
Self-testing
5.12.2
216
Self-testing
5.12.3
67
Shelf life
5.1.8
72
Side-effects
5.1.9
119
Single fault conditions
5.8.1
141
Size
5.8.3
105
Software
5.8.1
107
Software as a medical device
5.8.1
253
Specimen stability
7.2.1
65
Stability
5.1.8
287
Standardized units
7.2.3
36
State of the art
5.1.3
124
State of the art
5.8.2
241
State of the art
7.2.1
60
Stress resistance
5.1.6
243
Traceability of calibrators and controls
7.2.1
279
Traceability of values
7.2.2
203
Training
5.12.2
30
Update control measures
5.1.2
18
Updating
5.1.2
180
Usage variations (user technique, usage environment)
5.12.1
46
User training
5.1.3
289
User understanding
7.2.3
230
Valid result
5.12.3
134
Validation
5.8.2
239
Validation
7.2.1
269
Validation
7.2.1
132
Verification
5.8.2
220
Verification
5.12.3
226
Warning
5.12.3
94
Well-being
5.2.2
&A
Page &P
ep key concepts with clusters
Chronology
Keyword
Section
Cluster 1
Cluster 2
Cluster 3
1
Performance
5.1.1
Analytical performance
Clinical performance
2
Intendeded conditions of use
5.1.1
Intended use
3
Safety
5.1.1
Safety
4
Perform as intended
5.1.1
Intended use
Safety
5
Acceptable risks
5.1.1
Risk and Alarms
6
Patient benefits
5.1.1
Benefit-risk
Clinical performance
7
Health
5.1.1
Clinical performance
9
Risk management system
5.1.2
Risk and Alarms
11
Quality
5.1.2
Analytical performance
Clinical performance
12
Safety
5.1.2
Safety
14
Performance
5.1.2
Analytical performance
Clinical performance
15
Continuous, iterative risk management
5.1.2
Risk and Alarms
17
MD life cycle
5.1.2
Life cycle
18
Updating
5.1.2
Control
Safety
20
Risk management plan
5.1.2
Risk and Alarms
21
Identify and analyze hazards
5.1.2
Risk and Alarms
Safety
22
Risk
5.1.2
Risk and Alarms
23
Intended use
5.1.2
Intended use
24
Foreseeable misuse
5.1.2
Safety
Risk and Alarms
25
Risk elimination
5.1.2
Risk and Alarms
26
Risk control
5.1.2
Risk and Alarms
27
Continuous, iterative risk management
5.1.2
Risk and Alarms
28
Continuous, iterative risk management
5.1.2
Risk and Alarms
30
Update control measures
5.1.2
Control
Safety
32
Risk control measures
5.1.3
Risk and Alarms
34
Safety principles compliance
5.1.3
Safety
36
State of the art
5.1.3
38
Risk control
5.1.3
Risk and Alarms
39
Safe design
5.1.3
Safety
40
Alarms
5.1.3
Risk and Alarms
Safety
42
Risks that cannot be eliminated
5.1.3
Risk and Alarms
Documentation
44
Alarms
5.1.3
Risk and Alarms
46
User training
5.1.3
Documentation
Intended user
48
Residual risk information for user
5.1.4
Documentation
Intended use
50
Risk reduction
5.1.5
Risk and Alarms
52
Risk reduction
5.1.5
Risk and Alarms
54
Intended usage environment
5.1.5
Intended use
Documentation
57
Consider user knowledge
5.1.5
Intended user
60
Stress resistance
5.1.6
Safety
External factors
62
Intended use
5.1.6
Intended use
63
Expected life of device
5.1.6
Documentation
Safety
65
Stability
5.1.8
Life cycle
Change management
Data quality
67
Shelf life
5.1.8
Life cycle
70
Risk
5.1.9
Risk and Alarms
72
Side-effects
5.1.9
Risk and Alarms
75
Clinical evaluation
5.2.1
Clinical performance
77
Benefit-risk determination
5.2.1
Benefit-risk
79
Clinical investigation report
5.2.1
Clinical performance
81
Published scientific literature
5.2.1
Clinical performance
83
Clinical experience
5.2.1
Clinical performance
86
Ehtical prinicples
5.2.2
Ethical compliance
88
Declaration of Helsinki
5.2.2
Ethical compliance
90
Rights
5.2.2
Ethical compliance
92
Safety
5.2.2
Safety
94
Well-being
5.2.2
Benefit-risk
Clinical performance
96
Pre-study protocol review
5.2.2
Ethical compliance
98
Informed consent
5.2.2
Ethical compliance
100
Leftover specimen
5.2.2
Ethical compliance
103
Electronic programmable systems
5.8.1
Software
105
Software
5.8.1
107
Software as a medical device
5.8.1
109
Accuracy
5.8.1
Analytical performance
Safety
111
Reliability
5.8.1
Analytical performance
Technical interfaces
113
Precision
5.8.1
Safety
Analytical performance
115
Safety
5.8.1
Safety
117
Performance
5.8.1
Analytical performance
Intended use
119
Single fault conditions
5.8.1
Risk and Alarms
121
Risk reduction
5.8.1
Risk and Alarms
124
State of the art
5.8.2
126
Principles of development life cycle (e.g., rapid development cycles, frequent changes, the cumulative effect of changes)
5.8.2
Life cycle
Safety
128
Risk management (e.g., changes to system, environment, and data)
5.8.2
Risk and Alarms
130
Information security (e.g., safely implement updates)
5.8.2
Technical interfaces
132
Verification
5.8.2
Analytical performance
Control
134
Validation
5.8.2
Analytical performance
Control
136
Change management process
5.8.2
Change management
139
Mobile computing platforms
5.8.3
Technical interfaces
141
Size
5.8.3
Technical interfaces
143
Contrast ratio of the screen
5.8.3
Technical interfaces
145
Connectivity
5.8.3
Technical interfaces
147
Memory
5.8.3
Technical interfaces
149
External factors related to their use (varying environment as regards level of light or noise)
5.8.3
External factors
151
Minimum requirements
5.8.4
Technical interfaces
153
Hardware
5.8.4
Technical interfaces
155
IT networks characteristics
5.8.4
Technical interfaces
157
IT security measures
5.8.4
Technical interfaces
159
Protection against unauthorized access
5.8.4
Safety
Technical interfaces
161
Cybersecurity
5.8.5
Technical interfaces
Safety
Documentation
163
Protection against unauthorized access
5.8.5
Safety
Technical interfaces
165
Information [Manual]
5.10.1
Documentation
Intended use
167
Safety
5.10.1
Safety
169
Performance
5.10.1
Documentation
Intended user
171
Easily understood
5.10.1
Explainability
Intended user
Intended use
174
Lay user
5.12.1
Intended user
176
Self-testing
5.12.1
Intended use
Intended user
178
Intended use
5.12.1
Intended use
180
Usage variations (user technique, usage environment)
5.12.1
Intended use
Intended user
182
Instructions
5.12.1
Documentation
Intended use
184
Easy to understand
5.12.1
Explainability
Intended user
186
Easy to apply
5.12.1
Intended user
Documentation
188
Lay user
5.12.2
Intended user
190
Self-testing
5.12.2
Intended use
Intended user
192
Near-patient testing
5.12.2
Safety
Intended user
Intended use
195
Safety
5.12.2
Safety
197
Accuracy
5.12.2
Analytical performance
199
Instructions
5.12.2
Documentation
Intended use
201
Risk reduction
5.12.2
Risk and Alarms
203
Training
5.12.2
Documentation
Intended user
206
Risk reduction
5.12.2
Risk and Alarms
208
Risk of error
5.12.2
Risk and Alarms
210
Handling
5.12.2
Documentation
Intended use
212
Interpretation of results
5.12.2
Interpretability
Intended user
214
Lay users
5.12.3
Intended user
216
Self-testing
5.12.3
Intended use
Intended user
218
Near-patient testing
5.12.3
Safety
Intended user
220
Verification
5.12.3
Analytical performance
Control
222
Intended use
5.12.3
Intended use
224
Performance
5.12.3
Safety
Intended user
226
Warning
5.12.3
Risk and Alarms
Safety
228
Failure
5.12.3
Safety
Risk and Alarms
230
Valid result
5.12.3
233
Performance characteristics
7.2.1
Analytical performance
Clinical performance
235
Analytical performance
7.2.1
Analytical performance
237
Clinical performance
7.2.1
Clinical performance
239
Validation
7.2.1
Analytical performance
Control
241
State of the art
7.2.1
243
Traceability of calibrators and controls
7.2.1
Analytical performance
245
Accuracy of measurements (trueness and precision)
7.2.1
Analytical performance
Measurements
247
Analytical sensitivity/Limit of detection
7.2.1
Analytical performance
249
Analytical specificity
7.2.1
Analytical performance
251
Measuring interval/range
7.2.1
Analytical performance
253
Specimen stability
7.2.1
Analytical performance
255
Clinical performance
7.2.1
Clinical performance
257
Diagnostic/clinical sensitivity
7.2.1
Clinical performance
259
Diagnostic/clinical specificity
7.2.1
Clinical performance
261
Positive predictive value
7.2.1
Clinical performance
263
Negative predictive value
7.2.1
Clinical performance
265
Likelihood ratios
7.2.1
Clinical performance
267
Expected values in normal and affected populations.
7.2.1
Clinical performance
269
Validation
7.2.1
Analytical performance
Control
271
Control procedures
7.2.1
Safety
Control
273
Intended use
7.2.1
Intended use
275
Calibrators
7.2.2
Measurements
Analytical performance
277
Control materials
7.2.2
Measurements
Analytical performance
279
Traceability of values
7.2.2
Measurements
Data quality
281
Reference measurement procedures
7.2.2
Measurements
Data quality
283
Reference materials of higher order
7.2.2
Measurements
Data quality
285
Numerical values
7.2.3
Interpretability
287
Standardized units
7.2.3
Measurements
Data quality
Change management
289
User understanding
7.2.3
Documentation
Intended user
Change management
291
Performance evaluation
7.2.4
Intended user
Intended use
293
Intended use
7.2.4
Intended use
295
Intended user
7.2.4
Intended user
Explainability
297
Intended use environment
7.2.4
Intended use
299
Relevant population
7.2.4
Clinical performance
Data quality
301
Appropriate representation
7.2.4
Intended use
Data quality
303
Ethnicity
7.2.4
Data quality
Clinical performance
305
Gender
7.2.4
Clinical performance
307
Genetic diversity
7.2.4
Clinical performance
309
Representative population
7.2.4
Clinical performance
Data quality
311
Prevalence rates
7.2.4
Clinical performance
Data quality
&"Times New Roman,Regular"&12&A
&"Times New Roman,Regular"&12Page &P
ai4h concepts with clusters
Super-cluster name
Cluster-name
AI4H concept name
Super-cluster ID
Cluster ID
AI4H concept ID
Performance
Analytical performance
Two-class classification metrics
A
a
1
Performance
Analytical performance
Mutli-class classification metrics
A
a
2
Performance
Analytical performance
Regression metrics
A
a
3
Life Cycle
Change management
Evolution of the AI algorithm
D
a
1
Risk and Control
Control
Cross-validation
B
a
1
Risk and Control
Control
Statistical tests
B
a
2
Risk and Control
Control
Information criteria
B
a
3
Risk and Control
Control
Robustness validation
B
a
4
Risk and Control
Control
Out of sample testing
B
a
5
Risk and Control
Control
Attribution methods
B
a
6
Risk and Control
Data quality
Data diversity
B
b
1
Risk and Control
Data quality
Preprocessing
B
b
2
Risk and Control
Data quality
Normalization
B
b
3
Risk and Control
Data quality
Expert labels
B
b
4
Risk and Control
Data quality
Data collection procedure
B
b
5
Usability and Documentation
Documentation
Datasheets for data sets
C
a
1
Usability and Documentation
Documentation
Modelcards for ML models
C
a
2
Ethical Compliance
Ethical Compliance
FAT optimization objectives (“FAT training”)
F
a
1
Ethical Compliance
Ethical Compliance
FAT validation
F
a
2
Ethical Compliance
Ethical Compliance
Data acceptance and handling
F
a
3
Ethical Compliance
Ethical Compliance
Patient consent
F
a
4
Usability and Documentation
Explainability
see B) Risk and Control a) Control 6) Attribution methods (“Explainable AI (XAI)”)
C
b
1
Usability and Documentation
Explainability
Counterfactual explanations
C
b
2
Usability and Documentation
Intended use
Specification for inputs
C
c
1
Usability and Documentation
Intended use
see C) Usability and Documentation a) Documentation 1) Datasheets for data sets
C
c
2
Usability and Documentation
Intended use
see C) Usability and Documentation a) Documentation 2) Modelcards for ML models
C
c
3
Usability and Documentation
Interpretability
see B) Risk and Control a) Control 6) Attribution methods (“Explainable AI (XAI)”)
C
e
1
Life Cycle
Life Cycle
AI software life cycle
D
b
1
Performance
Measurements
see B) Risk and Control b) Data quality
A
d
1
Risk and Control
Risk and Alarms
Uncertainty quantification
B
c
1
Risk and Control
Risk and Alarms
Outlier detection
B
c
2
Risk and Control
Safety
Robust training
B
d
1
Dependencies
Technical Interfaces
Compression of AI4H models
E
b
1
Dependencies
Technical Interfaces
Response time
E
b
2
Dependencies
Technical Interfaces
Memory
E
b
3
Dependencies
Technical Interfaces
Compute
E
b
4
Dependencies
Technical Interfaces
Networking
E
b
5
Dependencies
Technical Interfaces
Operating system
E
b
6
Dependencies
Technical Interfaces
Displays
E
b
7
Dependencies
Technical Interfaces
Sensors for input data
E
b
8
&"Times New Roman,Regular"&12&A
&"Times New Roman,Regular"&12Page &P
clusters with super-clusters
Clusters
Super-clusters
My order
Analytical performance
Performance
1
Benefit-risk
Performance
1
Clinical performance
Performance
1
Measurements
Performance
1
Control
Risk and control
2
Data quality
Risk and control
2
Risk and Alarms
Risk and control
2
Safety
Risk and control
2
Documentation
Usability and documentation
3
Explainability
Usability and documentation
3
Intended use
Usability and documentation
3
Intended user
Usability and documentation
3
Interpretability
Usability and documentation
3
Change management
Life cycle
4
Life cycle
Life cycle
4
External factors
Dependencies
5
Technical interfaces
Dependencies
5
Ethical compliance
Ethical compliance
6
Software
&"Times New Roman,Regular"&12&A
&"Times New Roman,Regular"&12Page &P
Language:English
Score: 552492.4
-
https://www.itu.int/en/ITU-T/f...ents/all/FGAI4H-G-038-A01.xlsx
Data Source: un
ATM performance parameters
4. What additional parameters are needed to characterize the performance of new ATM transfer capabilities?
(...) What parameters are required to describe the throughput performance of ATM connections?
Performance objectives, QoS class definitions and performance allocation
7. (...) 15. What is the performance of AAL type 2 switched connections?
Availability performance
16.
Language:English
Score: 552421.9
-
https://www.itu.int/ITU-T/2001-2004/com13/sg13-q7.html
Data Source: un
planned anticipated performance gaps
ATM performance? and their reasons?
SSSSTTTTEEEEPPPP 1111 1 2 3 5
What are the What are the How to measure What are the performance
ATM community performance performance? targets? (...) What is the current and
planned ATM performance?
What are the current and
anticipated performance gaps and their reasons?
Language:English
Score: 552265.7
-
https://www.icao.int/WACAF/Doc...APIRG/APIRG18/Docs/wp11_en.pdf
Data Source: un